FAP Antibody (6D394): sc-71094

FAP Antibody (6D394) is a mouse monoclonal IgG antibody that detects fibroblast activation protein (FAP) in human samples through applications such as immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Anti-FAP antibody (6D394) targets a cell surface glycoprotein and serine protease that plays a crucial role in both embryonic development and cancer progression. FAP (6D394) monoclonal antibody recognizes a protein involved in the remodeling of developing tissues during embryogenesis, which is essential for proper organ formation and function. In the context of cancer, FAP promotes cellular proliferation and is often expressed in epithelial cancer-associated fibroblasts, making FAP a potential biomarker for tumor progression and a target for therapeutic intervention. FAP consists of N-glycosylated proteolytically inactive subunits that form an integral membrane gelatinase, and FAP expression can be influenced by cytokines such as IL-1 and oncostatin M, particularly in osteoarthritic conditions. FAP expression is co-localized with matrix metalloproteinases MMP-1 and MMP-13, as well as CD44 variants, highlighting FAP′s involvement in the tumor microenvironment. Mice deficient in FAP exhibit fertility but also present with developmental defects and altered cancer susceptibility, underscoring FAP′s significance in both normal physiology and disease states.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

FAP Antibody (6D394) References:

1. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.  |  Kraman, M., et al. 2010. Science. 330: 827-30. PMID: 21051638
2. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.  |  Loktev, A., et al. 2019. J Nucl Med. 60: 1421-1429. PMID: 30850501
3. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications.  |  Millul, J., et al. 2021. Proc Natl Acad Sci U S A. 118: PMID: 33850024
4. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.  |  Xu, M., et al. 2022. J Nucl Med. 63: 952-958. PMID: 34593598
5. PET of Fibroblast-Activation Protein for Breast Cancer Diagnosis and Staging.  |  Mankoff, DA. and Sellmyer, MA. 2022. Radiology. 302: 48-49. PMID: 34636639
6. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.  |  Wen, X., et al. 2022. Theranostics. 12: 422-433. PMID: 34987657
7. Fibroblast Activation Protein Triggers Release of Drug Payload from Non-internalizing Small Molecule Drug Conjugates in Solid Tumors.  |  Zana, A., et al. 2022. Clin Cancer Res. 28: 5440-5454. PMID: 36215129
8. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy.  |  Shahvali, S., et al. 2023. Drug Deliv Transl Res. 13: 2041-2056. PMID: 36840906
9. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.  |  Zboralski, D., et al. 2023. Eur J Nucl Med Mol Imaging. 50: 2621-2635. PMID: 37086273
10. Fibroblast Activation Protein-Targeted PET/CT with 18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with 18F-FDG PET/CT.  |  Xu, W., et al. 2024. J Nucl Med. 65: 40-51. PMID: 37884330

The preferred FAP antibody is FAP Antibody (F11-24): sc-65398.